There are media reports that China is preparing to vaccinate 50 million people against the new crown (Chinese Communist virus) before the Chinese lunar calendar. However, the vaccine developed by China has not completed clinical trials and is feared to face serious diplomatic, political and economic consequences.
According to the South China Morning Post, Beijing is planning to distribute 100 million doses of the two-dose inactivated vaccines manufactured by Sinopharm and Sinovac, with the timing of the distribution likely to vary by province. But officials were told that the first phase of 50 million doses of the vaccine would be administered by Jan. 15 next year, and the second phase would be completed by Feb. 5, in order to finish administering the vaccine before the Chinese New Year holiday, which begins Feb. 11, to reduce the risk of spreading the disease during the holiday.
However, according to a current affairs analysis published in the Financial Times on February 16, entitled “Problems to be solved when Chinese vaccines go global,” not only have none of the vaccines developed in China gone through all the procedures required for vaccine development, but some vaccines have not even published the data of the first phase of animal experiments and entered the human clinical trial stage, which may lead to subsequent problems, according to Cao Xin, secretary-general of the International Public Opinion Research Center of the Chahar Institute.
According to Cao Xin’s analysis, according to internationally accepted vaccine development procedures, new vaccines should go through clinical trials on animals and humans and be proven to be qualified before they can be used on humans, and the data and information of animal trials should be released before entering the third phase of human clinical trials. However, according to the statement made by Chinese Vice Premier Sun Chunlan recently, vaccines made in China have not gone through all the internationally recognized research and development processes, and none of the Chinese vaccines have received approval from the State Drug Administration, so there are legal problems. In contrast, the vaccines that have begun to be used in the U.K. and the U.S. all have legal approvals.
In the article, Cao Xin also said that if the procedures are not handled properly, China could face political, diplomatic and economic consequences if the Chinese vaccine is about to be exported.
In addition to the international impact of the Chinese vaccine, the situation of the vaccine and the health of the Chinese people in China should also receive continued attention from the outside world.
Recent Comments